|
Prescription Drug Search
Product Request Form
Arzerra is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Arzerra becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about CancerDrugsDirect.com
List of countries where we can ship Arzerra:
- Antigua and Barbuda
- Aruba
- Australia
- Austria
- Bahrain
- Bangladesh
- Bermuda
- Bolivia
- Brazil
- Cook Islands
- Costa Rica
- Cyprus
- Estonia
- European Union
- Fiji
- Georgia
- Germany
- Greece
- Guam
- Hong Kong
- Hungary
- India
- Ireland
- Latvia
- Malta
- New Zealand
- Nicaragua
- Norway
- Panama
- Paraguay
- Qatar
- Russian Federation
- Saint Lucia
- Saudi Arabia
- Slovakia
- Switzerland
- Tunisia
- United Kingdom, UK
- United States, US
- Uruguay
Latest news releases on Arzerra:
Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com
Arzerra(r) net sales increased 32% over Q1 2011 New Drug Application for ofatumumab submitted in Japan Amended protocol for ofatumumab Phase III head to head study vs rituximab in DLBCL; moved estimated primary data readout forward Improved ...
DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 - finanztreff
increase was mainly driven by higher Arzerra(r) royalties and the inclusion of one milestone under our collaboration with Lundbeck. -- Operating expenses decreased 5% from DKK 145 million in the first quarter of 2011 to DKK 138 million in the first quarter of 2012.
Gilead's Hematology Pipeline: Transformative And Under-Appreciated - Seekingalpha.com
Rituxan + placebo. Pharmacyclics will evaluate Ibrutinib as a single agent versus Arzerra (similar mechanism to that of Rituxan). Notably, this trial will be an open label study, so patients and physicians will know what each patient gets. Theoretically ...
MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - Market Wire
approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...
Genmab A/S : Daratumumab Clinical Data to Be Presented at ASCO and EHA - 4-traders (press release)
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's ...
ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) - Inside Fidelity
(Abstract No. 6507.) Abstract No. 6508 reports on interim results from a phase Ib/II study combining ibrutinib with Glaxo's Arzerra in patients with relapsed/refractory CLL. The overall response rate to the combination therapy was 100%, all partial responses.
Cancer Monoclonal Antibodies Market to 2015 - PR-USA.net
Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years. 5.3.9 Arzerra/Ofatumumab
